Propanc Biopharma, Inc.
NNASDAQ:PPCBCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- James Andrew Nathanielsz
- Full Time Employees
- 2
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 302, 6 Butler Street Camberwell VIC Australia 3124
- IPO Date
- Aug 15, 2025
- CIK
- 0001517681
- Website
- propanc.com
- Similar Companies
- Business
- Propanc Biopharma, Inc. is a clinical-stage biopharmaceutical company headquartered in Melbourne, Australia, specializing in the development of novel cancer treatments for patients with pancreatic, ovarian, and colorectal cancers. The company’s core product is PRP, a proprietary pancreatic proenzyme formulation designed as a long-term therapy to prevent tumor recurrence and metastasis by targeting and eradicating cancer stem cells. PRP acts as an epithelial-mesenchymal transition (EMT) modulator, suppressing tumor growth, inhibiting angiogenesis, and inducing cancer cell death. Propanc is also developing a synthetic backup compound called Rec-PRP as part of its drug pipeline. The company’s product development is supported by collaborations with academic institutions including the Universities of Jaén and Granada in Spain, where joint drug discovery and research programs are underway. In recent developments, Propanc is advancing PRP toward a Phase 1B First-In-Human clinical trial scheduled for 2026 involving 30 to 40 advanced cancer patients, with GMP manufacturing scale-up achieving high purity standards. The company has initiated a strategic pharma partnering initiative with prominent cancer research institutes and global biomedical companies to support clinical development and commercialization. Additionally, Propanc has embarked on a strategic acquisition plan targeting Digital Asset Treasury (DAT) companies trading below market cap to net asset value, aiming to diversify its asset base and strengthen its financial position. This initiative is backed by a securities purchase agreement for up to $100 million with Hexstone Capital LLC, a family office with investments in digital assets, enabling Propanc to accelerate its R&D and expand its development programs beyond oncology. Propanc Biopharma was founded with a focus on enzyme therapy for solid tumors and holds a robust intellectual property portfolio with numerous granted patents and pending applications covering key markets. The company operates primarily in Australia with ongoing research partnerships in Spain and targets major pharmaceutical markets worldwide with its innovative proenzyme-based therapeutic approach designed to revolutionize cancer treatment by reducing metastasis and improving patient survival outcomes. Propanc’s efforts are geared toward addressing the high unmet medical need in solid tumor cancers, initially focusing on pancreatic, ovarian, and colorectal cancer indications, with plans to broaden its clinical pipeline and commercial reach. The strategic shift toward integrating digital asset acquisitions alongside its core biopharma business marks a unique financing and growth model in the biotechnology sector, aiming to enhance shareholder value while maintaining a strong focus on its proprietary proenzyme cancer therapies. Propanc’s management team has strengthened its leadership recently with new appointments to support this transformative phase of clinical and corporate growth. Overall, Propanc Biopharma combines innovative scientific research with strategic financial initiatives to advance cancer treatment and shareholder value in a competitive biopharmaceutical environment.
Company News
Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans
Propanc Biopharma's Lead Asset PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells
Propanc Biopharma Announces Publication of Pilot Study Demonstrating Potent Anti-Tumor Efficacy of PRP Pancreatic Proenzyme Formulation in Pancreatic & Ovarian Cancer
Propanc Biopharma Inc (NASDAQ:PPCB) Sees Significant Increase in Short Interest
Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines' Daraxonrasib
Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results
Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015
Propanc Biopharma Positions PRP's EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc.
Propanc Biopharma to Initiate World-First Phase 1b First-in-Human Study of PRP in February 2027
Revolution Medicines' Pancreatic Cancer Drug Approval Validates Microcap Propanc Biopharma's Breakthrough Survival Results
Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for PRP Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit
Propanc Biopharma Clears Path for World-First Phase 1b Clinical Study of Breakthrough Cancer Therapy PRP
Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers
Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models
Propanc Biopharma Completes First Tranche of $5.0 Million Share Repurchase Program
Propanc Biopharma Publishes Evaluation of Recombinant Trypsinogen & Chymotrypsinogen in Peer Reviewed Journal
Propanc Biopharma Signs MOU with Avance Clinical Pty Ltd
Propanc Biopharma Initiates $5.0 Million Share Repurchase Program
Propanc Biopharma's CEO Tours European CDMO & Plans for GMP Production of PRP for Phase 1b, FIH Study
Propanc Biopharma Authorizes $5.0 Million Share Repurchase Program